VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Analyst Ratings

FRA:VX1 • US92532F1003

404.85 EUR
+5.3 (+1.33%)
Last: Feb 20, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Buy % Consensus

80

ChartMill assigns a Buy % Consensus number of 80% to VX1.DE. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 449.01. This target is 10.91% above the current price.
  • VX1.DE was analyzed by 39 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about VX1.DE.
  • In the previous month the buy percentage consensus was at a similar level.
  • VX1.DE was analyzed by 39 analysts, which is quite many. So the average rating should be quite meaningful.

Related screens

Find peers with buy consensus above 85%
VX1.DE Historical Analyst RatingsVX1.DE Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 10 20 30 40

Price Target & Forecast

Price Low Median Mean High 404.85304.39455.84449.01553.35 - -24.81% 12.59% 10.91% 36.68%

Related screens

Find peers 30% below price target
VX1.DE Current Analyst RatingVX1.DE Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 5 10 15
Up and Down Grades
Date Firm Action Rating
2021-07-30 RBC Capital Maintains Outperform
2021-07-30 SVB Leerink Maintains Underperform
2021-07-30 Morgan Stanley Maintains Equal-Weight
2021-07-30 Piper Sandler Maintains Overweight
2021-07-20 SVB Leerink Downgrade Market Perform -> Underperform
2021-07-01 Raymond James Initiate Market Perform
2021-06-14 SVB Leerink Maintains Market Perform
2021-06-14 Truist Securities Maintains Buy
2021-06-14 Piper Sandler Maintains Overweight
2021-06-11 Cantor Fitzgerald Maintains Overweight
2021-06-11 RBC Capital Maintains Outperform
2021-06-11 Stifel Maintains Buy
2021-06-11 Barclays Maintains Overweight
2021-06-11 Baird Maintains Outperform
2021-06-11 Goldman Sachs Maintains Buy
2021-06-11 Morgan Stanley Maintains Equal-Weight
2021-06-11 Citigroup Maintains Buy
2021-04-30 Morgan Stanley Maintains Equal-Weight
2021-04-19 Morgan Stanley Maintains Equal-Weight
2021-02-23 Baird Upgrade Neutral -> Outperform

VERTEX PHARMACEUTICALS INC / VX1.DE FAQ

What is the average price target for VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

39 analysts have analysed VX1.DE and the average price target is 449.01 EUR. This implies a price increase of 10.91% is expected in the next year compared to the current price of 404.85.


Can you provide the consensus rating for VERTEX PHARMACEUTICALS INC stock?

The consensus rating for VERTEX PHARMACEUTICALS INC (VX1.DE) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.